Uma M. Borate
Expertise in
15
conditions

Dr. Uma M. Borate

Hematology
The Osuccc-James
460 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
18 Years of Experience
Expertise in
15
conditions
The Osuccc-James
460 W 10th Ave, 
Columbus, OH 

Overview

Uma Borate is a Hematologist practicing medicine in Columbus, Ohio. She has been practicing medicine for over 18 years.

Dr. Borate is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 84 peer reviewed articles and participating in 17 clinical trials. Dr. Borate is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Ohio State University State Health System
Fairfield Medical Center

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

The Osuccc-James
460 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Samalizumab, BI-836858, Daunorubicin, Cytarabine, Azacitidine, AG-221, Entospletinib, Decitabine, Pevonedistat, AG-120, Gilteritinib, AZD5153, Venetoclax, TP-0903, AZD5991
Study Phase: Phase 2/Phase 3
Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ruxolitinib, Venetoclax
Study Phase: Phase 1
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
A Pilot Study of Ivosidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH1
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 15, 2026
Intervention Type: Procedure, Drug
Study Drugs: Cytarabine, Daunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Midostaurin
Study Phase: Phase 1
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2026
Intervention Type: Other, Drug
Study Phase: Phase 2
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
A Phase I/II, Open-Label, Multi-Center Study Evaluating the Safety and Efficacy of Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms
Enrollment Status: Terminated
Publish Date: April 24, 2026
Intervention Type: Procedure, Drug
Study Drugs: Liposomal Daunorubicin, Liposomal Cytarabine, Ruxolitinib
Study Phase: Phase 1/Phase 2
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
A Phase Ib, Multicenter, Open-label Platform Study of Select Drug Combinations in Adult Patients With Lower Risk (Very Low, Low, or Intermediate Risk) Myelodysplastic Syndrome
Enrollment Status: Terminated
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drugs: MBG453 Anti-TIM3 Monoclonal Antibody, NIS793 Anti-TGFBeta Monoclonal Antibody, Canakinumab
Study Phase: Phase 1
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drugs: Decitabine, PDR001, MBG453, Azacitidine
Study Phase: Phase 1
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Drugs: ASTX660, ASTX727
Study Phase: Phase 1
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
View 8 Less Clinical Trials

84 Total Publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.7 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kami Maddocks is a Hematologist practicing medicine in Columbus, Ohio. Dr. Maddocks is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Maddocks is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
 (3.1 miles away)
614-293-9441
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Spero Cataland is a Hematologist practicing medicine in Columbus, Ohio. Dr. Cataland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy. Dr. Cataland is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Select Specialty Hosp-Columbus

410 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
614-293-7677
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Woyach is a Hematologist practicing medicine in Columbus, Ohio. Dr. Woyach is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration. Dr. Woyach is currently accepting new patients.

Frequently Asked Questions about Dr. Uma M. Borate

How do I make an appointment with Dr. Uma M. Borate?

You can book an appointment with Dr. Uma M. Borate by calling their office at 614-293-3196. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Uma M. Borate a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Uma M. Borate is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Uma M. Borate specialize in?

While Dr. Uma M. Borate is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Uma M. Borate participate in research or clinical trials?

Yes. Dr. Uma M. Borate has published 84 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Uma M. Borate's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Uma M. Borate accept my insurance?

Dr. Uma M. Borate accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-293-3196 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Borate's expertise for a condition
ConditionClose
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile